Evidence map›Paper›PMID 29438375›Full record

ArticleBritish journal of cancer2018

Telomere length and genetics are independent colorectal tumour risk factors in an evaluation of biomarkers in normal bowel.

Ceres Fernandez-Rozadilla, Christiana Kartsonaki, Connor Woolley, Michael McClellan, Deb Whittington, Gareth Horgan, Simon Leedham, Skirmantas Kriaucionis, James East, Ian Tomlinson

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Ceres Fernandez-RozadillaMolecular and Population Genetics Laboratory University of Oxford, Oxford OX3 7BN, UK.
Christiana KartsonakiClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, Old Road Campus, Oxford OX3 7DQ, UK.
Connor WoolleyMolecular and Population Genetics Laboratory University of Oxford, Oxford OX3 7BN, UK.
Michael McClellanLudwig Institute for Cancer Research, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.
Deb WhittingtonTranslational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK.
Gareth HorganTranslational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK.
Simon LeedhamTranslational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK.
Skirmantas KriaucionisLudwig Institute for Cancer Research, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.
James EastLudwig Institute for Cancer Research, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.
Ian TomlinsonMolecular and Population Genetics Laboratory University of Oxford, Oxford OX3 7BN, UK.
University of Oxford · GBJohn Radcliffe Hospital · GBCell and Gene Therapy Catapult · GBLudwig Cancer Research · GBUniversity of Birmingham · GB

Funding

Biotechnology and Biological Sciences Research Council BB/M001873/1Cancer Research UK 16459Cancer Research UK 16581Wellcome TrustWellcome Trust 090532/Z/09/Z
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) screening might be improved by using a measure of prior risk to modulate screening intensity or the faecal immunochemical test threshold. Intermediate molecular biomarkers could aid risk prediction by capturing both known and unknown risk factors.

methodsWe sampled normal bowel mucosa from the proximal colon, distal colon and rectum of 317 individuals undergoing colonoscopy. We defined cases as having a personal history of colorectal polyp(s)/cancer, and controls as having no history of colorectal neoplasia. Molecular analyses were performed for: telomere length (TL); global methylation; and the expression of genes in molecular pathways associated with colorectal tumourigenesis. We also calculated a polygenic risk score (PRS) based on CRC susceptibility polymorphisms.

resultsBowel TL was significantly longer in cases than controls, but was not associated with blood TL. PRS was significantly and independently higher in cases. Hypermethylation showed a suggestive association with case:control status. No gene or pathway was differentially expressed between cases and controls. Gene expression often varied considerably between bowel locations.

conclusionsPRS and bowel TL (but not blood TL) may be clinically-useful predictors of CRC risk. Sample collection to assess these biomarkers is feasible in clinical practice, especially where population screening uses flexible sigmoidoscopy or colonoscopy.

Indexed as

Telomere HomeostasisAdultAgedAged, 80 and overBiomarkers, TumorCase-Control StudiesColonColonoscopyColorectal NeoplasmsDNA MethylationEarly Detection of CancerFemaleGene Regulatory NetworksHumansMaleMiddle AgedBiomarkers, Tumor

Identifiers

PMID29438375
PMCPMC5846076
OpenAlexW4240309808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.